Alexander COVID News-Dr. Paul Elias Alexander's Newsletter

Share this post

More evidence that hydroxychloroquine plus azithromycin was beneficial early? Yes, we have evidence also of benefit late in the COVID sequelae;

palexander.substack.com

Discover more from Alexander COVID News-Dr. Paul Elias Alexander's Newsletter

COVID-19 and SARS-CoV-2: natural immunity; innate immunity; vaccines and immune pressure; no vaccines for children; early outpatient treatment; lockdowns; school closures and mask mandates and vaccine mandates and emergency powers and truck convoy
Over 38,000 subscribers
Continue reading
Sign in

More evidence that hydroxychloroquine plus azithromycin was beneficial early? Yes, we have evidence also of benefit late in the COVID sequelae;

Dr. Paul Alexander
Apr 13, 2023
82
Share this post

More evidence that hydroxychloroquine plus azithromycin was beneficial early? Yes, we have evidence also of benefit late in the COVID sequelae;

palexander.substack.com
24
Share

SOURCE:

Alexander COVID News-Dr. Paul Elias Alexander's Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

https://www.medrxiv.org/content/10.1101/2023.04.03.23287649v1

Retrospective monocentric cohort study, not the most robust study design yet the findings are very promising and overall the study is well done.

‘Total 30,423 COVID-19 patients were analysed (86 refused the analysis of their data) including 30,202 with available treatment data, and 535 died (1.77%). '

All-cause mortality was very low among patients < 50 years (8/15,925 (0.05%)) and among outpatients treated with HCQ-AZ (21 deaths out of 21,135 (0.1%), never exceeding 0.2% regardless of epidemic period).

HCQ-AZ treatment was associated with a significantly lower mortality rate than no HCQ-AZ after adjustment for sex, age, period and patient care setting (adjusted OR (aOR) 95% confidence interval (CI) 0.55, 0.45-0.68).

The effect was greater among outpatients (71% death protection rate) than among inpatients (45%). In a subset of 16,063 patients with available comorbidities and vaccinations status, obesity (2.01, 1.23-3.29), chronic respiratory disease (2.93, 1.29-6.64), and immunodeficiency (4.01, 1.69-9.50), on the one hand, and vaccination (0.29, 0.12-0.67) and HCQ-AZ treatment (0.47, 0.29-0.76), on the other hand, were independent factors associated with mortality.

HCQ, alone or in any association, was associated with significant protection from death among outpatients (0.41, 0.21-0.79) and inpatients (0.59, 0.47-0.73).’

Researchers concluded that ‘HCQ prescribed early or late protects in part from COVID-19-related death.’

Alexander COVID News-Dr. Paul Elias Alexander's Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

82
Share this post

More evidence that hydroxychloroquine plus azithromycin was beneficial early? Yes, we have evidence also of benefit late in the COVID sequelae;

palexander.substack.com
24
Share
24 Comments
Share this discussion

More evidence that hydroxychloroquine plus azithromycin was beneficial early? Yes, we have evidence also of benefit late in the COVID sequelae;

palexander.substack.com
Milehijules
Writes milehijules on the 4IR
Apr 13

c19early.org a single site with almost 3000 studies on hundreds of different treatments that include not just prescribed drugs but also OTC, vitamins, etc. It provides a summary of effectiveness, it even calculates cost per life saved for the most common treatments, and it provides detailed pages for most treatments with links to all the individual studies.

Expand full comment
Reply
Share
5 replies
Thomas A Braun RPh
Apr 13

When are you going to drill down and expose the DOD/CIA role in this Covid con?

Expand full comment
Reply
Share
22 more comments...
Top
New
Community

No posts

Ready for more?

© 2023 Paul
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing